Free Trial

Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com

Oramed Pharmaceuticals logo with Medical background

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Monday.

Separately, HC Wainwright reiterated a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

View Our Latest Stock Report on Oramed Pharmaceuticals

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP remained flat at $2.38 during midday trading on Monday. The stock had a trading volume of 66,159 shares, compared to its average volume of 136,130. The business's fifty day moving average is $2.39 and its 200 day moving average is $2.41. The stock has a market cap of $96.70 million, a price-to-earnings ratio of 9.15 and a beta of 1.77. Oramed Pharmaceuticals has a fifty-two week low of $1.67 and a fifty-two week high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.21. As a group, equities research analysts predict that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Murchinson Ltd. lifted its position in Oramed Pharmaceuticals by 23.2% in the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock worth $4,369,000 after purchasing an additional 320,495 shares during the period. Renaissance Technologies LLC boosted its position in shares of Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock worth $81,000 after purchasing an additional 10,774 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth approximately $68,000. Finally, XTX Topco Ltd acquired a new stake in Oramed Pharmaceuticals during the second quarter valued at approximately $40,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

(Get Free Report)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Election warning coming true… (From Porter & Company) (Ad)

Should you invest $1,000 in Oramed Pharmaceuticals right now?

Before you consider Oramed Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.

While Oramed Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines